Boehringer to pay up to 210 million euros in ViraTherapeutics oncology deal with option to buy company
Privately-held German pharma Boehringer Ingelheim has announced a deal with ViraTherapeutics to jointly develop a next generation oncolytic virus therapy platform and to investigate the Austrian biotech’s lead candidate vesicular stomatitis virus glycoprotein (VSV-GP) alone and in combination with other therapies
The Innsbruck-based company has developed the technology with joint support from its lead investors EMBL Ventures and Boehringer Ingelheim Venture Fund (BIVF), and will now be responsible for preclinical and clinical testing of VSV-GP in Phase I trials.
Under the terms of the deal, which could be worth up to 210 million euros ($235.5 million), Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze